The Effect of Erythropoietin Usage in Renal Function After Kidney Transplantation, in Early Phase, in Contrast to Placebo Group
- Registration Number
- NCT00617474
- Lead Sponsor
- Labbafinejhad Hospital
- Brief Summary
The study hypothesis is that erythropoietin usage after kidney transplantation, in early phase, can improve the outcome for patients and their graft increasing patient and graft survival.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Hb: >8 and <10 gr/dl
- Age: >18 and <55 years
- Cholesterol: <300 mg/dl
- Triglyceride: <400 mg/dl
- First Transplantation
- Protocol of Immunosuppression: CSA + MMF + Prednisolone
- Systolic BP: <14
- Diastolic BP: <9
Exclusion Criteria
- History of specified cardiac disease
- Second Transplantation or more
- Hb: <7gr/dl
- The patient needs to infusion of blood
- Evidence of local or systemic infection, at the time of EPO injection
- Presence of ATN / DGF after transplantation
- Presence of emergent hypertension
- High risk patients ( Like; PRA>50%)
- Past history of hypersensitivity
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Placebo Patients group with anemia that treated by placebo 1 Erythropoietin Group of patient with anemia, that treated by erythropoietin
- Primary Outcome Measures
Name Time Method We will study the well-being of renal function by evaluation of plasma Cr,GFR,PTDA scan & biopsy proven(If it is necessary to prove the rejection)about measuring of patient - graft survival. May,2008
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms explain EPO's effect on graft survival in NCT00617474?
How does Erythropoietin compare to standard anemia treatments post-kidney transplant?
Are there specific biomarkers that predict EPO response in renal transplant recipients?
What adverse events are associated with early-phase EPO use in kidney transplantation?
What combination therapies with EPO are being explored for improved renal function post-transplant?